8-K: Pharma-Bio Serv 2026 Annual Meeting Results

Sentiment:

Annual Meeting Results


Pharma-Bio Serv, Inc. successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of Irving Wiesen and the ratification of its independent auditors.

Summary

  • The 2026 Annual Meeting of Stockholders was held on May 15, 2026.
  • Irving Wiesen was elected as a Class I director with 10,208,071 votes for and 195,625 votes withheld.
  • Shareholders ratified the selection of Crowe PR PSC as the independent certified public accountants for the fiscal year ending October 31, 2026, with 13,241,794 votes in favor.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing standard administrative compliance rather than a change in company fundamentals.

Positives

  • Successful re-election of board leadership ensures continuity.
  • Strong shareholder support for the appointment of Crowe PR PSC as independent auditors.

Negatives

  • Presence of 2,839,645 broker non-votes regarding the director election indicates a significant portion of shares held in street name did not provide voting instructions.

Risks

  • Reliance on broker participation for quorum and voting outcomes.

Future Outlook

The company continues its operations with the confirmed board and audit oversight for the remainder of the 2026 fiscal year.

Industry Context

StockSavvy.ai notes that routine annual meeting filings like this are standard corporate governance procedures and generally do not signal shifts in operational strategy or market positioning.

Comparison to Industry Standards

  • The ratification of auditors and election of directors via proxy is consistent with standard U.S. public company governance practices.
  • The voting turnout is typical for small-cap entities where retail and broker-held shares represent a significant portion of the float.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Class I DirectorN/AIrving Wiesen2026-05-15Elected at Annual Meeting

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Board CompositionElection of Irving Wiesen as Class I Director.2026-05-15Maintains board stability.

Stakeholder Impact

  • Shareholders have confirmed board representation and audit oversight.

Next Steps

  • Commencement of audit services by Crowe PR PSC for the fiscal year ending October 31, 2026.

Key Dates

DateDescription
2026-05-15Date of the 2026 Annual Meeting of Stockholders and filing date.
2026-10-31Fiscal year end for which auditors were ratified.
2029-05-15Expiration of the term for the newly elected Class I director.

Keywords

Pharma-Bio Serv, Annual Meeting, Proxy Voting, Corporate Governance, Board Election

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.